About the company
Seagen, formerly known as Seattle Genetics, has established itself as a prominent biotech firm in the field of cancer treatment. Through their innovative antibody-drug conjugate technology, they develop and commercialize therapies aimed at combating various types of cancers. At the heart of Seagen's approach is the utilization of monoclonal antibodies, which possess remarkable targeting abilities. These antibodies can recognize and bind specifically to cancer cells, allowing for the delivery of potent cell-killing agents directly to the diseased cells. This precision targeting not only enhances the effectiveness of the treatment but also minimizes damage to healthy cells, thereby reducing side effects for patients. One of Seagen's most successful therapies is Adcetris, which has obtained regulatory approval for treating six different indications of lymphomas, including Hodgkin lymphoma and T-cell lymphoma. This groundbreaking drug has revolutionized the treatment landscape for these diseases, offering new hope for patients who previously had limited options. Adcetris works by specifically targeting and annihilating cancer cells, while sparing healthy tissues. In addition to Adcetris, Seagen has developed several other approved products that have shown efficacy in combating different types of cancer. Padcev, for example, has been approved for the treatment of advanced bladder cancer, providing a significant advancement in the management of this challenging disease. Tukysa, on the other hand, has been specifically formulated to combat HER2-positive breast cancer, offering patients a targeted treatment option that can improve outcomes. Seagen's Tivdak is another example of their commitment to introducing novel therapies, as it has been approved for the treatment of recurrent or metastatic cervical cancer. Seagen's dedication to cancer research goes beyond their existing portfolio of products; they are actively engaged in numerous ongoing oncology programs in pivotal trials. These programs focus on developing and evaluating new treatment options for various types of cancer, aiming to broaden the range of effective therapies available to patients. Recognized for their groundbreaking advancements, Seagen also licenses their antibody-drug conjugate technology to other leading biotechnology and pharmaceutical companies. This partnership approach allows for the wider application of Seagen's innovative technology across the industry, fostering collaboration and accelerating the development of new treatments. With a profound commitment to improving patients' lives, Seagen continues to lead the way in developing cutting-edge cancer therapies. By harnessing the power of antibody-drug conjugate technology and actively engaging in clinical trials, Seagen is dedicated to bringing hope and transformative treatments to those affected by cancer.
Website: https://www.seagen.com
Data updated: April 30, 2026
